Breaking News
Get 50% Off 0
📌 New AI-picked stocks coming soon. 3 picks from last month are already up +30%...
Get early access
Close

HitGen Inc (688222)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
23.65 -0.07    -0.30%
07:59:59 - Closed. Currency in CNY
Type:  Equity
Market:  China
ISIN:  CNE1000040G3 
  • Volume: 36,295,270
  • Bid/Ask: 23.65 / 23.66
  • Day's Range: 23.03 - 24.79
HitGen 23.65 -0.07 -0.30%

HitGen Inc Company Profile

 
Get an in-depth profile of HitGen Inc, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

483

Equity Type

ORD

HitGen Inc. operates as a drug discovery research platform for small molecules and nucleic acid drugs in China and internationally. Its technology platform includes DNA-encoded library technology; fragment-based drug discovery and structure-based drug design technologies; emerging technology platforms for synthetic therapeutic oligonucleotide technology; and targeted protein degradation technology. The company’s product pipeline includes HG146, a selective HDAC inhibitor for multiple myeloma and solid tumor; HG030, a second generation NTRK/ROS1 inhibitor tablet for solid tumor; HG153 a Menin-MLL tablet; HG248; and HG 381, an immune-oncology agonist for cancer, as well as HGP0508, a small molecule for anti-inflammatory therapeutics for inflammation; HGP1069, a ROCK2 inhibitor eye drop. Further, it offers target validation, hit identification, hit-to-lead optimization, lead optimization, preclinical studies and IND, clinical development, and integrated drug discovery services. Additionally, the company focus on oncology and immuno-oncology, inflammatory and autoimmune diseases, ophthalmology, infectious, metabolic, and cardiovascular diseases. HitGen Inc. was founded in 2012 and is based in Chengdu, China.

Contact Information

Address Building C2 No.8, Huigu 1st East Road
Tianfu International Bio-Town Shuangliu District Chengdu, 610200
China
Phone 86 28 8519 7385
Fax -

Top Executives

Name Age Since Title
Li Jin 62 2019 Chairman & GM
Jianguo Li 64 2019 Director
Li Suibo 64 2022 Director
Yunpei Guo 78 2022 Independent Director
Lu Kai 72 2019 Vice Chairman
Lin Wang 57 2019 Director
Jianming Wang 43 2023 Director
Haizong Yu 61 2019 Independent Director
Xue Junfu 58 2022 Independent Director
Chenhui Xu 59 2019 Chairman of the Supervisory Board
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

688222 Comments

Write your thoughts about HitGen Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Apple
Continue with Google
or
Sign up with Email